OHSU

IRB #

IRB00010028

Title

Phase 2 Study of VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

To find out if VS-6063 (the study drug) will slow down the growth of non-small lung cancer (NSCLC)

Medical Condition(s)

NSCLC

Eligibility Criteria

1. Men or women at least 18 years of age
2. Diagnosis of KRAS-mutant NSCLC
3. Must have received at least one previous treatment (including at least one platinum-based chemotherapy)
4. Willing to submit tumor tissue to central lab for additional testing
5. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until the cancer gets worse or intolerable side effects

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Verastem, Inc.

Recruitment End

03/31/2015

Compensation Provided

No


Go Back